James Jarrett

698 total citations
34 papers, 432 citations indexed

About

James Jarrett is a scholar working on Infectious Diseases, Economics and Econometrics and Neurology. According to data from OpenAlex, James Jarrett has authored 34 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 5 papers in Economics and Econometrics and 3 papers in Neurology. Recurrent topics in James Jarrett's work include COVID-19 Clinical Research Studies (5 papers), Global Health Care Issues (3 papers) and HIV/AIDS Research and Interventions (3 papers). James Jarrett is often cited by papers focused on COVID-19 Clinical Research Studies (5 papers), Global Health Care Issues (3 papers) and HIV/AIDS Research and Interventions (3 papers). James Jarrett collaborates with scholars based in United Kingdom, United States and Italy. James Jarrett's co-authors include Zaid Chalabi, Ulla Griffiths, Phil Edwards, Ian Roberts, James Woodcock, Andy Haines, Miranda Mugford, David V. Gibson, Jennifer Quinn and Sarah Landis and has published in prestigious journals such as The Lancet, Climatic Change and Technovation.

In The Last Decade

James Jarrett

29 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Jarrett United Kingdom 10 105 67 64 58 44 34 432
Greg S. Dana United States 11 136 1.3× 30 0.4× 21 0.3× 54 0.9× 37 0.8× 12 434
Caroline Shaw New Zealand 20 297 2.8× 189 2.8× 58 0.9× 145 2.5× 20 0.5× 64 1.1k
Michael Zdeb United States 14 69 0.7× 134 2.0× 74 1.2× 251 4.3× 52 1.2× 20 1.1k
V. Sauerzapf United Kingdom 11 96 0.9× 43 0.6× 135 2.1× 69 1.2× 8 0.2× 11 639
Jingzhong Li China 11 88 0.8× 121 1.8× 56 0.9× 59 1.0× 11 0.3× 47 507
Michelle McMullen Canada 8 54 0.5× 331 4.9× 32 0.5× 28 0.5× 21 0.5× 16 674
James Cheshire United Kingdom 10 247 2.4× 77 1.1× 6 0.1× 132 2.3× 26 0.6× 23 658
Barbara A. McCann United States 5 50 0.5× 16 0.2× 43 0.7× 69 1.2× 18 0.4× 11 566
Zhenkun Wang China 18 16 0.2× 154 2.3× 28 0.4× 56 1.0× 52 1.2× 43 817
Matthew Clark United Kingdom 14 26 0.2× 22 0.3× 13 0.2× 30 0.5× 26 0.6× 24 659

Countries citing papers authored by James Jarrett

Since Specialization
Citations

This map shows the geographic impact of James Jarrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Jarrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Jarrett more than expected).

Fields of papers citing papers by James Jarrett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Jarrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Jarrett. The network helps show where James Jarrett may publish in the future.

Co-authorship network of co-authors of James Jarrett

This figure shows the co-authorship network connecting the top 25 collaborators of James Jarrett. A scholar is included among the top collaborators of James Jarrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Jarrett. James Jarrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jarrett, James, et al.. (2025). Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987–2023. ClinicoEconomics and Outcomes Research. Volume 17. 407–418.
2.
d’Ettorre, Gabriella, et al.. (2025). Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy. European Journal of Public Health. 35(5). 999–1006.
3.
Sullivan, Patrick S., et al.. (2025). Assessing the Benefits of Rapid Start Antiretroviral Therapy for Newly Diagnosed People with HIV in the United States. Advances in Therapy. 42(11). 5627–5638.
4.
5.
Barnieh, Lianne, et al.. (2023). Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources. Infectious Diseases and Therapy. 12(6). 1655–1665. 3 indexed citations
6.
Jarrett, James, et al.. (2023). Use of anti-viral therapies in hospitalised COVID-19 patients in the United Arab Emirates: a cost-effectiveness and health-care resource use analysis. BMC Health Services Research. 23(1). 383–383. 5 indexed citations
7.
Lu, Xiaoyan, et al.. (2022). Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. International Journal of Clinical Pharmacy. 45(2). 330–341. 6 indexed citations
8.
9.
Öksüz, E, S Malhan, Mustafa Sait Gönen, et al.. (2021). Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey. Advances in Therapy. 38(9). 4935–4948. 18 indexed citations
10.
Cleary, Maureen, James Davison, Tarekegn Geberhiwot, et al.. (2021). Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England. Orphanet Journal of Rare Diseases. 16(1). 38–38. 19 indexed citations
11.
Kenny, Thomas, et al.. (2021). Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement. Orphanet Journal of Rare Diseases. 16(1). 394–394. 6 indexed citations
12.
13.
14.
Lowin, Julia, et al.. (2014). Direct Costs of Unintended Pregnancy in the Russian Federation. Applied Health Economics and Health Policy. 13(1). 61–68. 3 indexed citations
15.
Jensen, Henning Tarp, Marcus Keogh-Brown, Richard Smith, et al.. (2013). The importance of health co-benefits in macroeconomic assessments of UK Greenhouse Gas emission reduction strategies. Climatic Change. 121(2). 223–237. 34 indexed citations
16.
Jarrett, James, James Woodcock, Ulla Griffiths, et al.. (2012). Effect of increasing active travel in urban England and Wales on costs to the National Health Service. The Lancet. 379(9832). 2198–2205. 156 indexed citations
17.
Gibson, David V., et al.. (2010). A set of Facilitators that drive the Technology Transfer Offices (TTO) in the actual effective and efficient practices of TT. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 1 indexed citations
18.
Jarrett, James & Miranda Mugford. (2006). Genetic Health Technology and Economic Evaluation. Applied Health Economics and Health Policy. 5(1). 27–35. 15 indexed citations
19.
Kockelman, Kara M., et al.. (2004). Right-of-Way Costs and Property Values: Estimating the Costs of Texas Takings and Commercial Property Sales Data. 4 indexed citations
20.
Gau, George W. & James Jarrett. (1992). Economic Impact Study: Balcones Canyonlands Conservation Plan. Texas ScholarWorks (Texas Digital Library). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Greg S. Dana Breakdown of academic impact, for papers by Caroline Shaw Breakdown of academic impact, for papers by Michael Zdeb Breakdown of academic impact, for papers by V. Sauerzapf Breakdown of academic impact, for papers by Jingzhong Li Breakdown of academic impact, for papers by Michelle McMullen Breakdown of academic impact, for papers by James Cheshire Breakdown of academic impact, for papers by Barbara A. McCann Breakdown of academic impact, for papers by Zhenkun Wang Breakdown of academic impact, for papers by Matthew Clark
Rankless by CCL
2026